Ribociclib and Endocrine Therapy in Premenopausal Women

Overview of Breast Cancer Diagnosis

Ribociclib, typically used in combination with endocrine therapy, is primarily prescribed for postmenopausal women. Recent research has explored its effectiveness in premenopausal women, a group that accounts for 20-50% of breast cancer diagnoses globally among those under 50 years of age. Traditionally, different drugs and endocrine therapy protocols have been recommended for premenopausal patients compared to their postmenopausal counterparts, but this approach is now being re-evaluated.

Understanding Endocrine Therapy

Patients diagnosed with estrogen-receptor positive breast cancer often continue a regimen of daily medications post-treatment. This ongoing treatment aims to influence the sex hormone estrogen, a strategy referred to as endocrine therapy in the medical community.

Research Study Overview

An international team of researchers conducted a pioneering study to investigate whether ribociclib, typically utilized for postmenopausal women, could also benefit premenopausal patients. Their findings were recently published in The Lancet.

Mechanism of Ribociclib

Ribociclib functions by inhibiting certain normal processes of cancer cells. In this study, researchers administered ribociclib alongside standard endocrine therapies for both premenopausal and postmenopausal women.

Clinical Trial Details

The clinical trial involved 672 premenopausal patients with advanced breast cancer, who were randomly assigned to one of two treatment groups. One group received ribociclib in conjunction with endocrine therapy, while the other was given a placebo alongside endocrine therapy. The placebo, which has no therapeutic effect, was utilized to ensure unbiased results, as patients were unaware of their treatment assignments.

Monitoring Patient Progress

Patients continued their treatment until their breast cancer worsened, caused significant illness, or they and their doctors opted to stop for other reasons. To assess cancer progression, doctors performed CT scans or MRIs every eight weeks during the first 18 months, followed by annual scans thereafter. Scans were discontinued if patients experienced worsening conditions or chose to withdraw.

Study Findings

The researchers followed the participants for an average of 19 months, measuring the duration in which breast cancer remained stable. Patients receiving ribociclib experienced a median progression-free survival of 23.8 months, compared to 13 months for those on the placebo.

Side Effects and Management

Patients treated with ribociclib exhibited lower white blood cell counts compared to those who received the placebo, which could compromise their immune response. However, healthcare providers effectively managed these side effects by adjusting ribociclib dosages.

Conclusions from the Study

The researchers reached two significant conclusions from their findings. Firstly, the combination of ribociclib with any form of endocrine therapy proved beneficial in halting disease progression in premenopausal breast cancer patients. Secondly, this study presents the first evidence of the effectiveness of frontline endocrine therapy in combating advanced breast cancer among premenopausal women.

References

(1) Romero D. Expanding ribociclib use. Nat Rev ClinOncol. 2018:1. doi:10.1038/s41571-018-0051-x.
(2) Tripathy D, Im S-A, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018. doi:10.1016/S1470-2045(18)30292-4.